Remove Licensing Remove Packaging Remove Regulations
article thumbnail

Animals Need Drugs Too, But Not Without CVM Approval

FDA Law Blog: Biosimilars

Specifically, CVM ensures that animal drugs are safe and effective, properly made, and adequately labeled and packaged; food-producing animals only take drugs that would be safe for humans to consume; pet foods and additives are safe; and educates the public, monitors the market, and encourages development of new animal health products.

Drugs 59
article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

Improvements in technology and changes to worldwide regulations in life sciences has led to an increase in the availability of clinical data. Remote trials, wearable devices and advancements in genomic sequencing means that clinical data is now more abundant than ever and is only set to grow. . Global efforts .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nine Key Takeaways from Dreamforce 2023

Perficient: Drug Development

Users can interact with the assistant in natural language, and it can offer additional actions beyond user queries, such as automatically completing tasks, providing recommendations, and answering questions. Free Data Cloud and Tableau Licenses Perhaps the biggest announcement to come out of Dreamforce, Salesforce is providing free Data Cloud (..)

article thumbnail

Do You Have a Combination Product, and Is It Drug-led or Device-led? Early Regulatory Insights

The Premier Consulting Blog

e) reveals more detail — and gray areas: Two or more regulated components, in one package (e.g., typical drug device, biologic device) Two or more separate components, co-packaged (e.g., The drug product is packaged and shipped as a solid powder. therapeutic drug/monoclonal antibody) Drug/device (e.g.,

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in July and August 2024

Agency IQ

What We Expect the FDA to do in July and August 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The following PDUFA dates were obtained from publicly available sources.

FDA 40
article thumbnail

What FDA’s Newest Gene Therapy Approval Tells Us About Durability: How Long is Long Enough?

FDA Law Blog: Drug Discovery

This product was developed by uniQure prior to being licensed to CSL Behring. However, with this most recent approval, FDA did not leave the question of durability as something to be answered postapproval, which signals to us that this issue looms large in FDA’s preapproval regulation of gene therapies.

Therapies 119
article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The standard for the audit used depends on the type of vendor and would include the applicable regulations and ICH guidelines. Q: What is the typical time period between the submission of the briefing package and the pre-IND meeting? The term drug substance and drug product are found in the NDA regulations 21 CFR 314.3,